{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T18:08:20Z","timestamp":1794593300752,"version":"4.9.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum RWTH Aachen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Reliable factors predicting the disease course of non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) are unavailable. Molecular subtypes have potential for prognostic stratification of muscle-invasive bladder cancer, while their value for CIS patients is unknown. Here, the prognostic impact of both clinico-pathological parameters, including CIS focality, and immunohistochemistry-based surrogate subtypes was analyzed in a cohort of high-risk NMIBC patients with CIS. In 128 high-risk NMIBC patients with CIS, luminal (KRT20, GATA3, ERBB2) and basal (KRT5\/6, KRT14) surrogate markers as well as p53 were analyzed in 213\u2013231 biopsies. To study inter-lesional heterogeneity of CIS, marker expression in independent CIS biopsies from different bladder localizations was analyzed. Clinico-pathological parameters and surrogate subtypes were correlated with recurrence-free (RFS), progression-free (PFS), cancer-specific (CSS), and overall survival (OS). Forty-six and 30% of CIS patients exhibited a luminal-like (KRT20-positive, KRT5\/6-negative) and a null phenotype (KRT20-negative, KRT5\/6-negative), respectively. A basal-like subtype (KRT20-negative, KRT5\/6-positive) was not observed. A significant degree of inter-lesional CIS heterogeneity was noted, reflected by 23% of patients showing a mixed subtype. Neither CIS surrogate subtype nor CIS focality was associated with patient outcome. Patient age and smoking status were the only potentially independent prognostic factors predicting RFS, PFS, OS, and PFS, respectively. In conclusion, further clarification of heterogeneity of surrogate subtypes in HR NMIBC and their prognostic value is of importance with regard to potential implementation of molecular subtyping into clinical routine. The potential prognostic usefulness of patient age and smoking status for high-risk NMIBC patients with CIS needs further validation.<\/jats:p>","DOI":"10.1007\/s00428-021-03054-0","type":"journal-article","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T21:02:57Z","timestamp":1614632577000},"page":"325-335","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer"],"prefix":"10.1007","volume":"479","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5447-3207","authenticated-orcid":false,"given":"Stefan","family":"Garczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Bischoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Golz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich-Carl","family":"von Rundstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Kn\u00fcchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Degener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,1]]},"reference":[{"key":"3054_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"3054_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrc3817","volume":"15","author":"MA Knowles","year":"2015","unstructured":"Knowles MA, Hurst CD (2015) Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 15:25\u201341. https:\/\/doi.org\/10.1038\/nrc3817","journal-title":"Nat Rev Cancer"},{"key":"3054_CR3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","volume":"76","author":"M Babjuk","year":"2019","unstructured":"Babjuk M, Burger M, Comp\u00e9rat EM, Gontero P, Mostafid AH, Palou J, van Rhijn BWG, Roupr\u00eat M, Shariat SF, Sylvester R, Zigeuner R, Capoun O, Cohen D, Escrig JLD, Hern\u00e1ndez V, Peyronnet B, Seisen T, Soukup V (2019) European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol 76:639\u2013657. https:\/\/doi.org\/10.1016\/j.eururo.2019.08.016","journal-title":"Eur Urol"},{"key":"3054_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/bju.14915","volume":"125","author":"J Taylor","year":"2020","unstructured":"Taylor J, Becher E, Steinberg GD (2020) Update on the guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int 125:197\u2013205. https:\/\/doi.org\/10.1111\/bju.14915","journal-title":"BJU Int"},{"key":"3054_CR5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.urology.2005.06.135","volume":"66","author":"RJ Sylvester","year":"2005","unstructured":"Sylvester RJ, van der Meijden A, Witjes JA, Jakse G, Nonomura N, Cheng C, Torres A, Watson R, Kurth KH (2005) High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 66:90\u2013107. https:\/\/doi.org\/10.1016\/j.urology.2005.06.135","journal-title":"Urology"},{"key":"3054_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1177\/1756287215599694","volume":"7","author":"DH Tang","year":"2015","unstructured":"Tang DH, Chang SS (2015) Management of carcinoma in situ of the bladder: best practice and recent developments. Ther Adv Urol 7:351\u2013364. https:\/\/doi.org\/10.1177\/1756287215599694","journal-title":"Ther Adv Urol"},{"key":"3054_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11934-018-0852-6","volume":"19","author":"TK Nykopp","year":"2018","unstructured":"Nykopp TK, Batista da Costa J, Mannas M, Black PC (2018) Current Clinical Trials in Non-muscle Invasive Bladder Cancer. Curr Urol Rep 19:101. https:\/\/doi.org\/10.1007\/s11934-018-0852-6","journal-title":"Curr Urol Rep"},{"key":"3054_CR8","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","volume":"166","author":"HW Herr","year":"2001","unstructured":"Herr HW, Sogani PC (2001) Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 166:1296\u20131299","journal-title":"J Urol"},{"key":"3054_CR9","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ, Weinstein JN, Kwiatkowski DJ, Lerner SP, Akbani R, Al-Ahmadie H, Albert M, Alexopoulou I, Ally A, Antic T, Aron M, Balasundaram M, Bartlett J, Baylin SB, Beaver A, Bellmunt J, Birol I, Boice L, Bootwalla MS, Bowen J, Bowlby R, Brooks D, Broom BM, Bshara W, Bullman S, Burks E, C\u00e1rcano FM, Carlsen R, Carvalho BS, Carvalho AL, Castle EP, Castro MAA, Castro P, Catto JW, Chagas VS, Cherniack AD, Chesla DW, Choo C, Chuah E, Chudamani S, Cortessis VK, Cottingham SL, Crain D, Curley E, Czerniak BA, Daneshmand S, Demchok JA, Dhalla N, Djaladat H, Eckman J, Egea SC, Engel J, Felau I, Ferguson ML, Gardner J, Gastier-Foster JM, Gerken M, Getz G, Gibb EA, Gomez-Fernandez CR, Gordenin DA, Guo G, Hansel DE, Harr J, Hartmann A, Herbert LM, Hinoue T, Ho TH, Hoadley KA, Holt RA, Hutter CM, Jones SJM, Jorda M, Kahnoski RJ, Kanchi RS, Kasaian K, Kim J, Klimczak LJ, Kwiatkowski DJ, Lai PH, Laird PW, Lane BR, Leraas KM, Lerner SP, Lichtenberg TM, Liu J, Lolla L, Lotan Y, Lu Y, Lucchesi FR, Ma Y, Machado RD, Maglinte DT, Mallery D, Marra MA, Martin SE, Mayo M, McConkey DJ, Meraney A, Meyerson M, Mills GB, Moinzadeh A, Moore RA, Mora Pinero EM, Morris S, Morrison C, Mungall KL, Mungall AJ, Myers JB, Naresh R, O\u2019Donnell PH, Ojesina AI, Parekh DJ, Parfitt J, Paulauskis JD, Sekhar Pedamallu C, Penny RJ, Pihl T, Porten S, Quintero-Aguilo ME, Ramirez NC, Rathmell WK, Reuter VE, Rieger-Christ K, Robertson AG, Sadeghi S, Saller C, Salner A, Sanchez-Vega F, Sandusky G, Scapulatempo-Neto C, Schein JE, Schuckman AK, Schultz N, Shelton C, Shelton T, Shukla SA, Simko J, Singh P, Sipahimalani P, Smith ND, Sofia HJ, Sorcini A, Stanton ML, Steinberg GD, Stoehr R, Su X, Sullivan T, Sun Q, Tam A, Tarnuzzer R, Tarvin K, Taubert H, Thiessen N, Thorne L, Tse K, Tucker K, Van Den Berg DJ, van Kessel KE, Wach S, Wan Y, Wang Z, Weinstein JN, Weisenberger DJ, Wise L, Wong T, Wu Y, Wu CJ, Yang L, Zach LA, Zenklusen JC, Zhang J(J), Zhang J, Zmuda E, Zwarthoff EC (2017) Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell 171:540\u2013556.e25. https:\/\/doi.org\/10.1016\/j.cell.2017.09.007","journal-title":"Cell"},{"key":"3054_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee I-L, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Czerniak B, Dinney CPN, McConkey DJ (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25:152\u2013165. https:\/\/doi.org\/10.1016\/j.ccr.2014.01.009","journal-title":"Cancer Cell"},{"key":"3054_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ebiom.2016.08.036","volume":"12","author":"V Dadhania","year":"2016","unstructured":"Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A, Guo CC, Dinney C, Cogdell DE, Zhang S, Lee S, Lee JG, Weinstein JN, Baggerly K, McConkey D, Czerniak B (2016) Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use. EBioMedicine 12:105\u2013117. https:\/\/doi.org\/10.1016\/j.ebiom.2016.08.036","journal-title":"EBioMedicine"},{"key":"3054_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/his.13763","volume":"74","author":"M Jung","year":"2019","unstructured":"Jung M, Kim B, Moon KC (2019) Immunohistochemistry of cytokeratin (CK) 5\/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma. Histopathology 74:483\u2013493. https:\/\/doi.org\/10.1111\/his.13763","journal-title":"Histopathology"},{"key":"3054_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00428-017-2064-8","volume":"470","author":"J Breyer","year":"2017","unstructured":"Breyer J, Wirtz RM, Otto W, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Eidt S, Denzinger S, Burger M, Hartmann A, on behalf of the BRIDGE Consortium (2017) In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival. Virchows Arch 470:267\u2013274. https:\/\/doi.org\/10.1007\/s00428-017-2064-8","journal-title":"Virchows Arch"},{"key":"3054_CR14","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00428-018-2354-9","volume":"472","author":"I Barth","year":"2018","unstructured":"Barth I, Schneider U, Grimm T, Karl A, Horst D, Gaisa NT, Kn\u00fcchel R, Garczyk S (2018) Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications. Virchows Arch 472:749\u2013758. https:\/\/doi.org\/10.1007\/s00428-018-2354-9","journal-title":"Virchows Arch"},{"key":"3054_CR15","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s13402-020-00524-6","volume":"43","author":"T Schnitzler","year":"2020","unstructured":"Schnitzler T, Ortiz-Br\u00fcchle N, Schneider U, Lurje I, Guricova K, Buchner A, Schulz GB, Heidenreich A, Gaisa NT, Kn\u00fcchel R, Garczyk S (2020) Pure high-grade papillary urothelial bladder cancer: a luminal-like subgroup with potential for targeted therapy. Cell Oncol (Dordr) 43:807\u2013819. https:\/\/doi.org\/10.1007\/s13402-020-00524-6","journal-title":"Cell Oncol (Dordr)"},{"key":"3054_CR16","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/his.13225","volume":"71","author":"A Hodgson","year":"2017","unstructured":"Hodgson A, Xu B, Downes MR (2017) p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant. Histopathology 71:296\u2013304. https:\/\/doi.org\/10.1111\/his.13225","journal-title":"Histopathology"},{"key":"3054_CR17","first-page":"138","volume":"8","author":"W Remmele","year":"1987","unstructured":"Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138\u2013140","journal-title":"Pathologe"},{"key":"3054_CR18","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1200\/JCO.2000.18.21.3651","volume":"18","author":"G Pauletti","year":"2000","unstructured":"Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Slamon DJ (2000) Assessment of Methods for Tissue-Based Detection of the HER-2\/neu Alteration in Human Breast Cancer: A Direct Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry. J Clin Oncol 18:3651\u20133664. https:\/\/doi.org\/10.1200\/JCO.2000.18.21.3651","journal-title":"J Clin Oncol"},{"key":"3054_CR19","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/0895-4356(95)00048-8","volume":"48","author":"P Peduzzi","year":"1995","unstructured":"Peduzzi P, Concato J, Feinstein AR, Holford TR (1995) Importance of events per independent variable in proportional hazards regression analysis II. Accuracy and precision of regression estimates. J Clin Epidemiol 48:1503\u20131510. https:\/\/doi.org\/10.1016\/0895-4356(95)00048-8","journal-title":"J Clin Epidemiol"},{"key":"3054_CR20","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1073\/pnas.1318376111","volume":"111","author":"JS Damrauer","year":"2014","unstructured":"Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, Yeh JJ, Milowsky MI, Iyer G, Parker JS, Kim WY (2014) Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A 111:3110\u20133115. https:\/\/doi.org\/10.1073\/pnas.1318376111","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3054_CR21","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","volume":"182","author":"J Fernandez-Gomez","year":"2009","unstructured":"Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pi\u00f1eiro L, Gonzalez M, Portillo J, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho JE, Rabadan M, Astobieta A, Montesinos M, Isorna S, Munta\u00f1ola P, Gimeno A, Blas M, Martinez-Pi\u00f1eiro JA (2009) Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model. J Urol 182:2195\u20132203. https:\/\/doi.org\/10.1016\/j.juro.2009.07.016","journal-title":"J Urol"},{"key":"3054_CR22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.eururo.2014.06.040","volume":"67","author":"P Gontero","year":"2015","unstructured":"Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V, Larr\u00e9 S, Di Stasi S, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Kiemeney LA, Colombo R, Briganti A, Babjuk M, Malmstr\u00f6m PU, Oderda M, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Spahn M, Johansson R, Frea B, Soukup V, Xylinas E, Dalbagni G, Karnes RJ, Shariat SF, Palou J (2015) Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with bacillus calmette-gu\u00e9rin: Results of a retrospective multicenter study of 2451 patients. Eur Urol 67:74\u201382. https:\/\/doi.org\/10.1016\/j.eururo.2014.06.040","journal-title":"Eur Urol"},{"key":"3054_CR23","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DWW, Kurth K (2006) Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials. Eur Urol 49:466\u2013477. https:\/\/doi.org\/10.1016\/j.eururo.2005.12.031","journal-title":"Eur Urol"},{"key":"3054_CR24","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","volume":"69","author":"S Cambier","year":"2016","unstructured":"Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, Van Andel G, Kirkels WJ, Da Silva FC, Oosterlinck W, Prescott S, Kirkali Z, Powell PH, De Reijke TM, Turkeri L, Collette S, Oddens J (2016) EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Gu\u00e9rin. Eur Urol 69:60\u201369. https:\/\/doi.org\/10.1016\/j.eururo.2015.06.045","journal-title":"Eur Urol"},{"key":"3054_CR25","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1016\/S0022-5347(05)64994-4","volume":"167","author":"TRL Griffiths","year":"2002","unstructured":"Griffiths TRL, Charlton M, Neal DE, Powell PH (2002) Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol 167:2408\u20132412","journal-title":"J Urol"},{"key":"3054_CR26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1442-2042.2008.02012.x","volume":"15","author":"A Takenaka","year":"2008","unstructured":"Takenaka A, Yamada Y, Miyake H, Hara I, Fujisawa M (2008) Clinical outcomes of bacillus Calmette-Gu\u00e9rin instillation therapy for carcinoma in situ of urinary bladder. Int J Urol 15:309\u2013313. https:\/\/doi.org\/10.1111\/j.1442-2042.2008.02012.x","journal-title":"Int J Urol"},{"key":"3054_CR27","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","volume":"62","author":"J Palou","year":"2012","unstructured":"Palou J, Sylvester RJ, Faba OR, Parada R, Pe\u00f1a JA, Algaba F, Villavicencio H (2012) Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Gu\u00e9rin. Eur Urol 62:118\u2013125. https:\/\/doi.org\/10.1016\/j.eururo.2011.10.029","journal-title":"Eur Urol"},{"key":"3054_CR28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","volume":"30","author":"J Hedegaard","year":"2016","unstructured":"Hedegaard J, Lamy P, Nordentoft I, Algaba F, H\u00f8yer S, Ulh\u00f8i BP, Vang S, Reinert T, Hermann GG, Mogensen K, Thomsen MBH, Nielsen MM, Marquez M, Segersten U, Aine M, H\u00f6glund M, Birkenkamp-Demtr\u00f6der K, Fristrup N, Borre M, Hartmann A, St\u00f6hr R, Wach S, Keck B, Seitz AK, Nawroth R, Maurer T, Tulic C, Simic T, Junker K, Horstmann M, Harving N, Petersen AC, Calle ML, Steyerberg EW, Beukers W, van Kessel KEM, Jensen JB, Pedersen JS, Malmstr\u00f6m PU, Malats N, Real FX, Zwarthoff EC, \u00d8rntoft TF, Dyrskj\u00f8t L (2016) Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. Cancer Cell 30:27\u201342. https:\/\/doi.org\/10.1016\/j.ccell.2016.05.004","journal-title":"Cancer Cell"},{"key":"3054_CR29","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00428-019-02593-x","volume":"475","author":"J Rebola","year":"2019","unstructured":"Rebola J, Aguiar P, Blanca A, Montironi R, Cimadamore A, Cheng L, Henriques V, Lobato-Faria P, Lopez-Beltran A (2019) Predicting outcomes in non-muscle invasive (Ta\/T1) bladder cancer: the role of molecular grade based on luminal\/basal phenotype. Virchows Arch 475:445\u2013455. https:\/\/doi.org\/10.1007\/s00428-019-02593-x","journal-title":"Virchows Arch"},{"key":"3054_CR30","doi-asserted-by":"publisher","first-page":"e0179602","DOI":"10.1371\/journal.pone.0179602","volume":"12","author":"D Sikic","year":"2017","unstructured":"Sikic D, Keck B, Wach S, Taubert H, Wullich B, Goebell PJ, Kahlmeyer A, Olbert P, Isfort P, Nimphius W, Hartmann A, Giedl J (2017) Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis. PLoS One 12:e0179602. https:\/\/doi.org\/10.1371\/journal.pone.0179602","journal-title":"PLoS One"},{"key":"3054_CR31","doi-asserted-by":"publisher","first-page":"11702","DOI":"10.1038\/s41598-017-11291-0","volume":"7","author":"MBH Thomsen","year":"2017","unstructured":"Thomsen MBH, Nordentoft I, Lamy P, Vang S, Reinert L, Mapendano CK, H\u00f8yer S, \u00d8rntoft TF, Jensen JB, Dyrskj\u00f8t L (2017) Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer. Sci Rep 7:11702. https:\/\/doi.org\/10.1038\/s41598-017-11291-0","journal-title":"Sci Rep"},{"key":"3054_CR32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.eururo.2018.09.003","volume":"75","author":"JI Warrick","year":"2019","unstructured":"Warrick JI, Sj\u00f6dahl G, Kaag M, Raman JD, Merrill S, Shuman L, Chen G, Walter V, DeGraff DJ (2019) Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants. Eur Urol 75:18\u201322. https:\/\/doi.org\/10.1016\/j.eururo.2018.09.003","journal-title":"Eur Urol"},{"key":"3054_CR33","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3233\/BLC-180176","volume":"4","author":"L Jakobsson","year":"2018","unstructured":"Jakobsson L, Chebil G, Marzouka NAD, Liedberg F, Sj\u00f6dahl G (2018) Low Frequency of Intratumor Heterogeneity in Bladder Cancer Tissue Microarrays. Bladder Cancer 4:327\u2013337. https:\/\/doi.org\/10.3233\/BLC-180176","journal-title":"Bladder Cancer"},{"key":"3054_CR34","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1442-2042.2005.01155.x","volume":"12","author":"T Habuchi","year":"2005","unstructured":"Habuchi T (2005) Origin of multifocal carcinomas of the bladder and upper urinary tract: Molecular analysis and clinical implications. Int J Urol 12:709\u2013716. https:\/\/doi.org\/10.1111\/j.1442-2042.2005.01155.x","journal-title":"Int J Urol"},{"key":"3054_CR35","doi-asserted-by":"publisher","first-page":"238","DOI":"10.12688\/f1000research.7210.1","volume":"5","author":"L Gay","year":"2016","unstructured":"Gay L, Baker A-M, Graham TA (2016) Tumour Cell Heterogeneity. F1000Research 5:238. https:\/\/doi.org\/10.12688\/f1000research.7210.1","journal-title":"F1000Research"},{"key":"3054_CR36","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0090-4295(99)80047-8","volume":"45","author":"RJM van Gils-Gielen","year":"1995","unstructured":"van Gils-Gielen RJM, Debruyne FMJ, Witjes WPJ, Witjes JA, Caris CTM, Oosterhof GON (1995) Risk factors in carcinoma in situ of the urinary bladder. Urology 45:581\u2013586. https:\/\/doi.org\/10.1016\/S0090-4295(99)80047-8","journal-title":"Urology"},{"key":"3054_CR37","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000492121","volume":"101","author":"SJ Kim","year":"2018","unstructured":"Kim SJ, Nam W, You D, Jeong IG, Song C, Hong B, Kim CS, Ahn H, Hong JH (2018) Prognostic Factors Related to Recurrence-Free Survival for Primary Carcinoma in situ of the Bladder after Bacillus Calmette-Gu\u00e9rin: A Retrospective Study. Urol Int 101:269\u2013276. https:\/\/doi.org\/10.1159\/000492121","journal-title":"Urol Int"},{"key":"3054_CR38","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.eururo.2012.08.025","volume":"63","author":"M Rink","year":"2013","unstructured":"Rink M, Furberg H, Zabor EC, Xylinas E, Babjuk M, Pycha A, Lotan Y, Karakiewicz PI, Novara G, Robinson BD, Montorsi F, Chun FK, Scherr DS, Shariat SF (2013) Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer. Eur Urol 63:724\u2013732. https:\/\/doi.org\/10.1016\/j.eururo.2012.08.025","journal-title":"Eur Urol"},{"key":"3054_CR39","doi-asserted-by":"publisher","first-page":"65.e9","DOI":"10.1016\/j.urolonc.2014.06.002","volume":"33","author":"AJ Grotenhuis","year":"2015","unstructured":"Grotenhuis AJ, Ebben CW, Aben KK, Witjes JA, Vrieling A, Vermeulen SH, Kiemeney LA (2015) The effect of smoking and timing of smoking cessation on clinical outcome in non-muscle-invasive bladder cancer. Urol Oncol Semin Orig Investig 33:65.e9\u201365.e17. https:\/\/doi.org\/10.1016\/j.urolonc.2014.06.002","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"3054_CR40","doi-asserted-by":"publisher","first-page":"406","DOI":"10.23736\/S0393-2249.19.03254-5","volume":"71","author":"R Hurle","year":"2019","unstructured":"Hurle R, Lazzeri M, Saita A, Naselli A, Guarneri A, Buffi NM, Lughezzani G, Fasulo V, Mondellini GM, Paciotti M, Domanico L, Peschechera R, Benetti A, Zandegiacomo S, Lista G, Pasini L, Guazzoni G, Casale P (2019) Predictive factors for progression of patients with carcinoma in situ of the bladder at long-term follow-up: Pure versus non-pure CIS. Minerva Urol Nefrol 71:406\u2013412. https:\/\/doi.org\/10.23736\/S0393-2249.19.03254-5","journal-title":"Minerva Urol Nefrol"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-021-03054-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-021-03054-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-021-03054-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T19:20:06Z","timestamp":1628968806000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-021-03054-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["3054"],"URL":"https:\/\/doi.org\/10.1007\/s00428-021-03054-0","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,1]]},"assertion":[{"value":"13 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The retrospective, anonymous study on archived human tissue material was conducted at the Helios University Hospital Wuppertal and the University Hospital RWTH Aachen in accordance with the requirements of the institutional review board of the University of Witten\/Herdecke (No. 55\/2019), the current version of the Declaration of Helsinki, and the good clinical practice guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}